Proteomics International Laboratories Ltd Asset Resilience Ratio
Proteomics International Laboratories Ltd asset resilience ratio. Proteomics International Laboratories Ltd (PIQ) has an Asset Resilience Ratio of 57.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Proteomics International Laboratories Lt defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Proteomics International Laboratories Ltd (2017–2025)
Asset resilience ratio of Proteomics International Laboratories Ltd from 2017 to 2025. This chart shows how Proteomics International Laboratories Ltd's Asset Resilience Ratio has changed over time. Read PIQ total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Proteomics International Laboratories Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Proteomics International Laboratories Lt.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$6.49 Million | 57.44% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$6.49 Million | 57.44% |
Asset Resilience Insights
- Very High Liquidity: Proteomics International Laboratories Ltd maintains exceptional liquid asset reserves at 57.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Proteomics International Laboratories Ltd Industry Peers by Asset Resilience Ratio
Compare Proteomics International Laboratories Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Proteomics International Laboratories Ltd Asset Resilience Ratio by Year (2017–2025)
Proteomics International Laboratories Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Proteomics International Laboratories Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 63.71% | AU$9.42 Million ≈ $6.66 Million |
AU$14.78 Million ≈ $10.46 Million |
+6.70pp |
| 2024-06-30 | 57.00% | AU$6.20 Million ≈ $4.39 Million |
AU$10.88 Million ≈ $7.69 Million |
-0.47pp |
| 2023-06-30 | 57.47% | AU$5.79 Million ≈ $4.10 Million |
AU$10.08 Million ≈ $7.13 Million |
+38.94pp |
| 2022-06-30 | 18.53% | AU$1.00 Million ≈ $707.56K |
AU$5.40 Million ≈ $3.82 Million |
-40.19pp |
| 2021-06-30 | 58.72% | AU$5.05 Million ≈ $3.57 Million |
AU$8.60 Million ≈ $6.08 Million |
+57.82pp |
| 2020-06-30 | 0.90% | AU$50.00K ≈ $35.38K |
AU$5.55 Million ≈ $3.93 Million |
-28.10pp |
| 2019-06-30 | 29.00% | AU$1.05 Million ≈ $742.94K |
AU$3.62 Million ≈ $2.56 Million |
-13.17pp |
| 2018-06-30 | 42.16% | AU$2.32 Million ≈ $1.64 Million |
AU$5.49 Million ≈ $3.89 Million |
+15.33pp |
| 2017-06-30 | 26.83% | AU$775.14K ≈ $548.46K |
AU$2.89 Million ≈ $2.04 Million |
-- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more